Generic Octreoscan Availability

Octreoscan is a brand name of indium pentetreotide in-111, approved by the FDA in the following formulation(s):

OCTREOSCAN (indium in-111 pentetreotide kit - injectable;injection)

  • Manufacturer: MALLINCKRODT
    Approval date: June 2, 1994
    Strength(s): 3mCi/ML [RLD]

Has a generic version of Octreoscan been approved?

No. There is currently no therapeutically equivalent version of Octreoscan available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Octreoscan. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis
    Patent 5,753,627
    Issued: May 19, 1998
    Inventor(s): Albert; Rainer & Krenning; Eric P. & Lamberts; Steven W. J. & Pless; Janos
    Assignee(s): Novartis AG
    Somatostatin peptides bearing at least one chelating group for a detectable element, said chelating group being linked to an amino group of said peptide, and said amino group having no significant binding affinity for somatostatin receptors, in free or salt form, are complexed with a detectable element and are useful as a pharmaceutical, e.g. a radiopharmaceutical for in vivo imaging of somatostatin receptor positive tumors or for therapy.
    Patent expiration dates:
    • May 19, 2015
      ✓ 
      Patent use: METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS
  • Chelated somatostatin peptides and complexes thereof, pharmaceutical compositions containing them and their use in treating tumors
    Patent 5,776,894
    Issued: July 7, 1998
    Inventor(s): Albert; Rainer & Krenning; Eric P. & Lamberts; Steven W. J. & Pless; Janos
    Assignee(s): Novartis AG
    Somatostatin peptides bearing at least one chelating group for a detectable element, said chelating group being linked to an amino group of said peptide, and said amino group having no significant binding affinity for somatostatin receptors, in free or salt form, are complexed with a detectable element and are useful as a pharmaceutical, e.g. a radiopharmaceutical for in vivo imaging of somatostatin receptor positive tumors or for therapy.
    Patent expiration dates:
    • July 7, 2015
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Therapeutic use of somatostatin peptides
    Patent 6,123,916
    Issued: September 26, 2000
    Inventor(s): Krenning; Eric Paul & Lamberts; Steven Willem Jan
    Assignee(s): Novartis AG
    The invention relates to a new pharmaceutical use of somatostatin peptides comprising on the terminal amino group a polyamino polycarboxylic group, in free form or in a pharmaceutically acceptable salt form, particularly in the manufacture of a medicament for treating disorders with an aetiology comprising or associated with excess of GH-secretion.
    Patent expiration dates:
    • September 26, 2017
      ✓ 
      Patent use: METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web4)